Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search help
15 results
  1. Nausea and Vomiting Related to Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK66056
    ... treating patients who experience delayed N&V with cisplatin regimens.[ 25 - 29 ][ Level of evidence: I ] Given their ... mg given each day of a 5-day cisplatin regimen provides additional antiemetic benefit, and it may add ...
  2. Rectal Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65965
    ... outcome when cetuximab is added to multiagent chemotherapy regimens containing bevacizumab. Evidence (cetuximab): For patients who have progressed on irinotecan-containing ...
  3. Excluded Studies - Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK310435
    ... al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014; ...
  4. Laryngeal Cancer Treatment (Adult) (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65746
    ... life (QOL) was not adversely affected by adding cetuximab to this platinum-based regimen.[ 11 ] Tumor EGFR gene copy number was not found to be a predictive biomarker for the efficacy of cetuximab plus platinum and fluorouracil as first-line therapy ...
  5. Forest plots and Summary ROC curves - Pancreatic cancer in adults: diagnosis and management - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK536650
    ... Average monthly Karnofsky performance score Figure 424 GEM/Cisplatin-CRT versus 5FU-CRT – Adverse effects, Grade 3/4 toxicities H.16.2. Different chemoradiotherapy regimens after induction chemotherapy Figure 425 GEM-CRT versus ...
  6. GRADE Tables - Pancreatic cancer in adults: diagnosis and management - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK536654
    ... 324K) Table 62. Full GRADE profile for gemcitabine/Cisplatin-based chemoradiotherapy ... regimens after induction chemotherapy Table 63. Full GRADE profile ...
  7. pdf2017MeshTreesWithChangesShown.pdf 
    https://www.nlm.nih.gov/.../2017MeshTreesWithChangesShown.pdf
    ... D01.234 D01.248 D01.248.249 Chlorates Cisplatin Hydrochloric Acid Chlorides Ammonium Chloride Cadmium Chloride Calcium ... Sulfate Hydroxylamine Quaternary Ammonium Compounds Azides Sodium Azide Cisplatin 588 Jul 15, 20162:38:26 PM Page ...
  8. Articles Excluded at Full-Text Screening by Reason - Progression-Free Survival: What Does It Mean for Psychological ... 
    https://www.ncbi.nlm.nih.gov/books/NBK137765
    ... Excluded. [ PubMed : 19917838 ] Refid: 1514. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel ... Level: 2, State: Excluded. [ PubMed : 19179556 ] Refid: 1518. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck ...
  9. Network Meta-Analysis (Mixed Treatment Comparison) and Economic Model on treatment of unresectable locally advanced ... 
    https://www.ncbi.nlm.nih.gov/books/NBK536651
    ... added for adverse events, chemoradiotherapy with gemcitabine and cisplatin becomes the preferred option at a £20,000 ... are considered ( Figure 14 ) chemoradiotherapy with gemcitabine and cisplatin becomes the preferred treatment option at the £20, ...
  10. Health economic evidence review - Oesophago-gastric cancer - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK535638
    ... Webb, A., et al., Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in ... Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma. ...
previous · 1 · 2 · next